Commentary

Video

Final OS Data for Pembrolizumab Plus Trastuzumab/Chemotherapy in Advanced HER2+ Esophageal, Gastric, and GEJ Cancer

Author(s):

Sakti Chakrabarti, MD,Mohammed Najeeb Al Hallak, MD, MS

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on final overall survival data from the KEYNOTE-811 trial.

Related Videos
Piotr Rutkowski, MD
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on data for neoadjuvant nivolumab plus ipilimumab in dMMR colon cancer.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.
Samuel J. Klempner, MD
Zhi Peng, MD
Related Content
Tislelizumab Plus Chemo for Advanced Gastric/GEJ Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
November 27th 2024

EC Approves Frontline Tislelizumab Plus Chemo for Advanced ESCC and Gastric/GEJ Cancer

Deol on the Importance of a Well-Rounded Fellowship Experience
September 26th 2022

Deol on the Importance of a Well-Rounded Fellowship Experience

Trevor Leong, MBBS, MD, FRANZCR
November 5th 2024

Preoperative Radiotherapy Plus Perioperative Chemo Improves pCR Rate but Not Survival in Resectable Gastric/GEJ Cancer

Karmanos Faculty Share Experiences and Career Insights as Women in Oncology
May 30th 2022

Karmanos Faculty Share Experiences and Career Insights as Women in Oncology

FDA
October 22nd 2024

FDA Approves Companion Diagnostic for Zolbetuximab in CLDN18.2+ Gastric/GEJ Cancer

The OncFive
October 19th 2024

The OncFive: Top Oncology News and Trends for the Week of 10/13